Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
Phase 2 Trial Recruiting: WOMBAT Study on Bipolar Androgen Therapy for Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxPhase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial results of KPG-121
/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 1/by MaxRecent Advances in Tumor Reversion Research
/in Preclinical Research/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/in Clinical Trial, Not PCa related/by MaxWhere Are We With Ferroptosis?
/in Observational, Post-hoc, Retrospective studies/by Max